

Delve Health integrates Wearables and Digital Endpoints

Delve Health expand its Clinical StudyPal platform with integrated wearable and sensor technologies to capture remote digital endpoints

GOLDEN VALLEY, MN, USA, March 23, 2021 /EINPresswire.com/ -- A New Paradigm for Capturing Real World Data in Clinical Research

Delve Health continues to expand its Clinical StudyPal platform with integrated wearables and sensor technologies to capture digital endpoints, including continuous vital signs, heart rate, motion, and behavioral monitoring. Delve Health's Clinical Analytics Platform provides real-time insight into biometric data, sleep and activity levels. The platform uses various algorithms to capture adverse event (AE) indicators and provide real-time notification to investigators, sites and study teams remotely without adding patient burden or introducing compliance risk.



Wearables and Mobile sensors that are now ubiquitous with patients can be leveraged to provide information that can help pharma and medical device companies access data they never had"

Wessam Sonbol

Digital endpoints captured automatically through the wearables include:

Biometrics: heart rate at rest, respiratory rate, skin and core body temperature

Behavioral monitoring: body position, activity level, sleep status

Symptomatic data: fall detection, chest tightness, cough and sneeze detection

Additionally, Clinical StudyPal collects task-based endpoints, such as blood pressure, blood oxygen levels,



EXPLORE THE DATA using Clinical StudyPal

70% of clinical trials are expected to incorporate wearables and sensors by 2025 for better patient safety.

Delve Health can help you safely ingrate devices in your clinical trial

95% Response Rate Achieved in 23 Studies

Using mobile apps and SMS to improve patient compliance, realize drug adherence, and automate tasks

Monitor Patients Remotely

DELVEHEALTH

Get to Patients, Wherever They Are

Clinical StudyPal reached over 150,000 patients worldwide

www.delvehealth.com

info@delvehealth.com

Delve Health integrates wearables into Clinical StudPal

heart rate variability, 6 Minute Walk readings, and electrocardiogram results. Patients are responsible for wearing the device to capture these endpoints automatically and they are reminded with alerts to ensure data timeliness and improved compliance. Endpoints are provided in near-real-time through encrypted cellular data.

Using Delve Health's Concierge Service coupled with Clinical StudyPal ensures that our team manages all aspects of digital sensors from the integration of the devices with the application and data platform to managing the logistics and operation of the wearables or devices globally.

"Ubiquitous Wearables, Mobile and Remote Sensors can be leveraged to provide information that can enable biopharma and medical device companies to access data in ways they never could before and thus change the way clinical research can be designed," says Wessam Sonbol (LinkedIn), co-founder and CEO of Delve Health. "99.9% of patient motions and activities occur outside of the doctor's office. We want to capture patient activities and track any possible adverse reactions remotely while reducing patient's burden. Our expanded offerings for FDA-approved wearable technology transforms study conduct by providing real-world evidence you can trust, while reducing, and in many cases eliminating, the need for site visits all while maintaining patient safety oversight."

Through the Delve Health solutions, the company allows pharmaceutical and medical device sponsors, research sites, and clinical trial participants to perform and automate critical clinical trial operational tasks including clinical trial digital recruitment, study execution, compliance, and patient retention from any location worldwide. Delve Health's modules span digital patient recruitment, remote consent (eConsent), patient-reported outcomes and surveys (ePRO), clinical outcomes assessment (eCOA), dosing management, remote vital sign management and sensor data collection. Clinical StudyPal seamlessly integrates all of this with home health and video visits to advance clinical research into the post-COVID-19 era.

"Our mission is to improve patient conduct in clinical trials, making it easier for them to be part of a clinical research study, while reducing their burden. Our technology can do so much more than digitizing the patient silos of the past. Collectively as an industry, it is our responsibility to enable new insights, new safety measures, and new levels of data analytics previously thought impossible without adding burden on patients, sites, or study teams. Wearable technology expands our offering of at-home digital endpoints to improve the accuracy and effectiveness of decentralized clinical trials," says Sonbol.

To request a demo or start a conversation about how Delve Health can transform your next trial, visit www.delvehealth.com or contact jmiller@delvehealth.com

About Delve Health

Delve Health has developed Clinical StudyPal as a platform to accelerate clinical trial enrollment and remote patient care, compliance, and retention. The company's sole mission is to improve patient engagement in clinical trials, while enhancing collaboration between researchers,

patients, and caregivers on-site and remotely. Clinical StudyPal is HIPAA, FDA CFR 21 Part 11, and GDPR compliant and validated, and is being used globally across different therapeutic areas. Learn more at www.delvehealth.com

Wessam Sonbol

Delve Health

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/537019267>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.